论文部分内容阅读
目的探讨原发性卵巢浆液性癌组织中Hugl-1和aPKC的表达及意义。方法选择浙江大学医学院附属妇产科医院2000年6月至2007年6月经手术切除的原发性卵巢浆液性癌组织79例,用免疫组化SP法检测Hugl-1和aPKC蛋白在其组织中的表达。同时检测Hugl-1和aPKC蛋白在25例正常卵巢组织,31例卵巢浆液性囊腺瘤,41例卵巢交界性浆液性肿瘤中的表达,并分析了Hugl-1和aPKC蛋白表达与卵巢癌临床病理参数间的关系。结果Hugl-1蛋白在卵巢浆液性癌组织、正常卵巢、浆液性囊腺瘤及交界性浆液性肿瘤中的强阳性表达率分别为12.7%、48%、58%、41.5%。癌组织中的表达显著低于其余3组,差异有统计学意义(P<0.001);aPKC蛋白在卵巢浆液性癌组织、正常卵巢、浆液性囊腺瘤及交界性浆液性肿瘤中的强阳性表达率分别为19%、0、0、0。癌组织中的表达显著高于其余3组,差异有统计学意义(P<0.001);Hugl-1和aPKC的表达与组织学分级、手术病理分期、淋巴结转移有一定的相关性(P<0.05)。Hugl-1和aPKC在卵巢癌组织中的表达不存在相关性(P>0.05)。结论Hugl-1和aPKC可能均参与了卵巢癌的发生与发展。
Objective To investigate the expression and significance of Hugl-1 and aPKC in primary ovarian serous carcinoma. Methods Seventy-nine cases of primary ovarian serous carcinoma resected surgically from June 2000 to June 2007 were collected from Affiliated Obstetrics and Gynecology Hospital of Zhejiang University School of Medicine. Immunohistochemical SP method was used to detect the expression of Hugl-1 and aPKC protein in their tissues In the expression. Meanwhile, the expression of Hugl-1 and aPKC protein in 25 cases of normal ovarian tissue, 31 cases of ovarian serous cystadenoma and 41 cases of ovarian borderline serous tumors were detected. The expressions of Hugl-1 and aPKC protein in ovarian cancer The relationship between pathological parameters. Results The positive rates of Hugl-1 protein in ovarian serous carcinoma, normal ovary, serous cystadenoma and borderline serous tumors were 12.7%, 48%, 58% and 41.5% respectively. The expression of aPKC protein in ovarian serous carcinoma, normal ovary, serous cystadenoma and borderline serous tumors was significantly higher than that in the other three groups (P <0.001) The expression rates were 19%, 0,0,0 respectively. The expression of Hugl-1 and aPKC was positively correlated with histological grade, pathological stage and lymph node metastasis (P <0.05) ). There was no correlation between the expression of Hugl-1 and aPKC in ovarian cancer (P> 0.05). Conclusions Both Hugl-1 and aPKC may participate in the occurrence and development of ovarian cancer.